<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03962361</url>
  </required_header>
  <id_info>
    <org_study_id>IIBPS-BIO-2015-56</org_study_id>
    <nct_id>NCT03962361</nct_id>
  </id_info>
  <brief_title>New Biomarkers of Neurological Outcome After a Sudden Cardiac Death</brief_title>
  <official_title>New Biomarkers of Neurological Outcome in Patients With Sudden Cardiac Death: Role of Circulating Microparticles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundaci처 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundaci처 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <brief_summary>
    <textblock>
      The aim of the project is to establish the value of circulating microparticles as a new&#xD;
      biomarker for neurological prognosis of patients recovered from sudden cardiac death who&#xD;
      remain comatose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study. Analytical, observational, longitudinal, retrospective and&#xD;
      prospective, non-randomized. Patients recovered from sudden cardiac death of ischemic cause&#xD;
      and remain comatose will be included in the protocol if they fit the pre-specified inclusion&#xD;
      criteria. Biological samples will be collected (at admission, at 24 and 72 hours) and stored&#xD;
      in the Biobank of Hospital de la Santa Creu i Sant Pau for further analysis. In addition&#xD;
      demographic, clinical and analytical variables will be collected. At the end of the&#xD;
      recruitment period, we will analyse the concentrations of circulating microparticles&#xD;
      according to ICCC-IIBSantPau methodology in the samples obtained. The primary outcome&#xD;
      variable will be the neurological status at Coronary Care Unit discharge and at 6 months. The&#xD;
      objective of the study will evaluate the relationship between the neurological status and the&#xD;
      blood concentrations of circulating microparticles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glasgow-Pittsburgh Cerebral Performance Categories Scale for neurological outcome.</measure>
    <time_frame>Change from Glasgow-Pittsburgh Cerebral Performance Categories Scale at 6 months</time_frame>
    <description>Good cerebral performance: conscious, alert, able to work, might have mild neurologic or psychologic deficit.&#xD;
Moderate cerebral disability: conscious, sufficient cerebral function for independent activities of daily life. Able to work in sheltered environment.&#xD;
Severe cerebral disability: conscious, dependent on others for daily support because of impaired brain function. Ranges from ambulatory state to severe dementia or paralysis.&#xD;
Coma or vegetative state: any degree of coma without the presence of all brain death criteria. Unawareness, even if appears awake (vegetative state) without interaction with environment; may have spontaneous eye opening and sleep/awake cycles. Cerebral unresponsiveness.&#xD;
Brain death: apnea, areflexia, EEG silence, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiovascular mortality</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">84</enrollment>
  <condition>Cardiac Sudden Death</condition>
  <condition>Hypoxia Brain</condition>
  <condition>Cell Membrane Microparticles</condition>
  <condition>Biomarkers</condition>
  <arm_group>
    <arm_group_label>Sudden cardiac death of ischemic cause</arm_group_label>
    <description>Patients admitted to the Coronary Care Unit for sudden cardiac death of ischemic cause and remain comatose (GCS &lt; 8 points).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Concentration of circulating microparticles.</intervention_name>
    <description>The microparticles contained in the blood sample will be isolated by ultracentrifugation and quantified by flow cytometry. The microparticles concentration will be determined by the number of microparticles per uL of plasma, based on the volume of the sample, the flow rate of the cytometer and the number of fluorescent events.</description>
    <arm_group_label>Sudden cardiac death of ischemic cause</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples from patients enrolled in the study will be collected at admission, at 24 and&#xD;
      at 72 hours. Blood collection will be obtained from arterial access whenever possible&#xD;
      (otherwise preferably central or peripheral venous lines will be used without using&#xD;
      tourniquet) and stored in tubes sodium citrate 3.8 %. Immediately after blood collection, the&#xD;
      proteolipid protein fraction will be obtained by centrifugation fraction. To do this ,&#xD;
      samples will be centrifuged twice to exclude any cell rest. The aliquots obtained will be&#xD;
      frozen first with liquid nitrogen and then stored at -80째C in the Biobank IIB Sant Pau until&#xD;
      further analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We will include patients who have suffered a sudden cardiac death of ischemic cause&#xD;
        admitted to the Coronary Care Unit of the Hospital de la Santa Creu i Sant Pau in Barcelona&#xD;
        from the date of commencement of the study. The sample will be retrospectively completed&#xD;
        with patients of the same features admitted to the unit since January 2012 and who have&#xD;
        biological samples stored in the Biobank of Hospital de la Santa Creu i Sant Pau.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 18 years old.&#xD;
&#xD;
          -  Patients recovered from a sudden cardiac death (in-hospital and out-of-hospital) with&#xD;
             return of spontaneous circulation (ROSC) (defined as systolic blood pressure &gt; 60 mmHg&#xD;
             or palpable pulse for &gt; 5 minutes) who remain unconsciousness (defined as a score on&#xD;
             the Glasgow Coma Scale &lt;8 ) for &gt; 5-10 minutes after ROSC.&#xD;
&#xD;
          -  Treated with hypothermia as recommended by the European guidelines for resuscitation (&#xD;
             2010)..&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-cardiac sudden death.&#xD;
&#xD;
          -  Active oncologic pathology .&#xD;
&#xD;
          -  Traumatic or spontaneous intra-cranial haemorrhage.&#xD;
&#xD;
          -  Inability to obtain required blood samples or refusal of the informed consent&#xD;
             necessary for it.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laia C Belarte, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundaci처 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Sudden Death</keyword>
  <keyword>Hypoxia Brain</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Cell-Derived Microparticles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Death</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Death, Sudden</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

